# \[e-drug\] Therapeutics Letter #58: Benign Prostatic Hypertrophy **URL:** \ **Category:** e-drug\ **Created:** [May 4, 2006, 12:29am UTC](https://talk.edrugplus.org/t/e-drug-therapeutics-letter-58-benign-prostatic-hypertrophy/25276 "2006-05-04T00:29:27Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![Ciprian\_D\_Jauca](https://avatars.discourse-cdn.com/v4/letter/c/a9adbd/32.png) [@Ciprian\_D\_Jauca](https://talk.edrugplus.org/u/Ciprian_D_Jauca)\ **Post date:** [May 4, 2006, 12:29am UTC](https://talk.edrugplus.org/t/e-drug-therapeutics-letter-58-benign-prostatic-hypertrophy/25276/1 "2006-05-04T00:29:27Z")
E-DRUG: Therapeutics Letter #58: Benign Prostatic Hypertrophy --------------------------------------------------- I would like to bring to your attention the March 2006 issue (#58) of the Therapeutics Letter: "Benign Prostatic Hypertrophy: An update on drug therapy" that has just been published on the Therapeutics Initiative web site at [http://www.ti.ubc.ca/pages/letter58.htm](http://www.ti.ubc.ca/pages/letter58.htm) In this Therapeutics Letter we summarize the currently available evidence of benefit and harm from alpha blockers and 5-α-reductase inhibitors in the treatment of benign prostatic hypertrophy (BPH). I invite you to drop by and have a look at this Letter. Please feel free to forward this message to any of your friends or colleagues that might be interested in this topic. We would appreciate receiving your comments on this Therapeutics Letter and its possible implications in clinical practice. Best regards, Ciprian Jauca Manager Therapeutics Initiative University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC V6T 1Z3 Canada Email: jauca@ti.ubc.ca Tel: +1 (604) 822-0700 Fax: +1 (604) 822-0701 Web: www.ti.ubc.ca